Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors von LEIJEN, Suzanne, MIDDLETON, Mark R, TESSIER, Jean J. L, SHOCHAT, Eliezer, BLOTNER, Steve, MERESSE NAEGELEN, Valerie, SCHELLENS, Jan H. M, EBERHARDT, Wilfried Ernst Erich, TRESCA, Patricia, KRAEBER-BODERE, Françoise, DIERAS, Veronique, SCHEULEN, Max E, GUPTA, Avinash, LOPEZ-VALVERDE, Vanesa, XU, Zhi-Xin, RUEGER, Ruediger

Volltext

Assessment of target-mediated uptake with immuno-PET: analysis of a phase I clinical trial with an anti-CD44 antibody von Jauw, Yvonne W. S., Huisman, Marc C., Nayak, Tapan K., Vugts, Danielle J., Christen, Randolph, Naegelen, Valerie Meresse, Ruettinger, Dominik, Heil, Florian, Lammertsma, Adriaan A., Verheul, Henk M. W., Hoekstra, Otto S., van Dongen, Guus A. M. S., Menke-van der Houven van Oordt, C. Willemien

Volltext

Phase 1 study of the immunotoxin LMB‐100 in patients with mesothelioma and other solid tumors expressing mesothelin von Hassan, Raffit, Alewine, Christine, Mian, Idrees, Spreafico, Anna, Siu, Lillian L., Gomez‐Roca, Carlos, Delord, Jean‐Pierre, Italiano, Antoine, Lassen, Ulrik, Soria, Jean‐Charles, Bahleda, Rastilav, Thomas, Anish, Steinberg, Seth M., Peer, Cody J., Figg, William D., Niederfellner, Gerhard, Méresse Naegelen, Valérie, Pastan, Ira

Volltext

First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tum... von Martinez-Garcia, Maria, Banerji, Udai, Albanell, Joan, Bahleda, Rastilav, Dolly, Saoirse, Kraeber-Bodéré, Françoise, Rojo, Federico, Routier, Emilie, Guarin, Ernesto, Xu, Zhi-Xin, Rueger, Ruediger, Tessier, Jean J L, Shochat, Eliezer, Blotner, Steve, Naegelen, Valerie Meresse, Soria, Jean-Charles

Volltext

First-in-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of R05126766, a First-in-Class Dual MEK/RAF Inhibitor in Patients with Solid Tum... von MARTINEZ-GARCIA, Maria, BANERJI, Udai, RUEGER, Ruediger, TESSIER, Jean J. L, SHOCHAT, Eliezer, BLOTNER, Steve, MERESSE NAEGELEN, Valerie, SORIA, Jean-Charles, ALBANELL, Joan, BAHLEDA, Rastilav, DOLLY, Saoirse, KRAEBER-BODERE, Françoise, ROJO, Federico, ROUTIER, Emilie, GUARIN, Ernesto, XU, Zhi-Xin

Volltext

Differences in the Biologic Activity of 2 Novel MEK Inhibitors Revealed by 18 F-FDG PET: Analysis of Imaging Data from 2 Phase I Trials von Kraeber-Bodéré, Françoise, Carlier, Thomas, Naegelen, Valérie Meresse, Shochat, Eliezer, Lumbroso, Jean, Trampal, Carlos, Nagarajah, James, Chua, Sue, Hugonnet, Florent, Stokkel, Marcel, Gleeson, Fergus, Tessier, Jean

Volltext

Differences in the Biologic Activity of 2 Novel MEK Inhibitors Revealed by ^sup 18^F-FDG PET: Analysis of Imaging Data from 2 Phase I Trials von Kraeber-Bodéré, Françoise, Carlier, Thomas, Naegelen, Valérie Meresse, Shochat, Eliezer, Lumbroso, Jean, Trampal, Carlos, Nagarajah, James, Chua, Sue, Hugonnet, Florent, Stokkel, Marcel, Gleeson, Fergus, Tessier, Jean

Volltext

Phase I Study of the Immunotoxin LMB-100 in Patients with Mesothelioma and Other Solid Tumors Expressing Mesothelin von Hassan, Raffit, Alewine, Christine, Mian, Idrees, Spreafico, Anna, Siu, Lillian L., Gomez-Roca, Carlos, Delord, Jean-Pierre, Italiano, Antoine, Lassen, Ulrik, Soria, Jean-Charles, Bahleda, Rastilav, Thomas, Anish, Steinberg, Seth M., Peer, Cody J., Figg, William D., Niederfellner, Gerhard, Naegelen, Valérie Méresse, Pastan, Ira

Volltext

Differences in the biologic activity of 2 novel MEK inhibitors revealed by 18F-FDG PET: analysis of imaging data from 2 phase I trials von Kraeber-Bodéré, Françoise, Carlier, Thomas, Naegelen, Valérie Meresse, Shochat, Eliezer, Lumbroso, Jean, Trampal, Carlos, Nagarajah, James, Chua, Sue, Hugonnet, Florent, Stokkel, Marcel, Gleeson, Fergus, Tessier, Jean

Volltext